138 related articles for article (PubMed ID: 34405028)
21. Immune checkpoint inhibitors combined with paclitaxel-based chemotherapy versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancer: result of a multicenter retrospective study.
Fang Y; Zhao Y; Yu X; Liu S; Tao G; Zhong H; Xiang H; Yang Y; Shi Z
J Gastrointest Oncol; 2024 Apr; 15(2):585-596. PubMed ID: 38756641
[TBL] [Abstract][Full Text] [Related]
22. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of combined therapy versus monotherapy based on immune checkpoint inhibitors and/or targeted drugs as salvage treatment for advanced urothelial carcinoma: a systematic review and meta-analysis.
Wei L; Gao L; Hu Z; Liu C
Transl Cancer Res; 2021 May; 10(5):2091-2107. PubMed ID: 35116530
[TBL] [Abstract][Full Text] [Related]
24. For which lung cancer patients is re-administration of immune checkpoint inhibitors effective?
Sasaki T; Tabata T; Yoshimura N
J Rural Med; 2021 Oct; 16(4):256-262. PubMed ID: 34707736
[No Abstract] [Full Text] [Related]
25. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
26. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study.
Zheng L; Fang S; Wu F; Chen W; Chen M; Weng Q; Wu X; Song J; Zhao Z; Ji J
Front Mol Biosci; 2020; 7():609322. PubMed ID: 33521054
[No Abstract] [Full Text] [Related]
28. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Wang S; Hao J; Wang H; Fang Y; Tan L
Oncoimmunology; 2018; 7(8):e1457600. PubMed ID: 30221052
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
31. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
[TBL] [Abstract][Full Text] [Related]
33. Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors.
Kim HR; Kang JH; Kim SH; Kim ST; Kim I; Min YJ; Shin SH; Oh SY; Lee GW; Lee JH; Ji JH; Huh SJ; Lee S
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884501
[TBL] [Abstract][Full Text] [Related]
34. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.
Dayyani F; Chao J; Lee FC; Taylor TH; Neumann K; Cho MT
Oncologist; 2024 Jun; ():. PubMed ID: 38823034
[TBL] [Abstract][Full Text] [Related]
36. The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy.
Gou M; Zhang Y; Liu T; Qu T; Si H; Wang Z; Yan H; Qian N; Dai G
Front Oncol; 2021; 11():655716. PubMed ID: 34211839
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
Zhang Z; Xie T; Zhang X; Qi C; Shen L; Peng Z
Chin J Cancer Res; 2020 Jun; 32(3):287-302. PubMed ID: 32694895
[TBL] [Abstract][Full Text] [Related]
38. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
Zhao D; Mambetsariev I; Li H; Chen C; Fricke J; Fann P; Kulkarni P; Xing Y; Lee PP; Bild A; Massarelli E; Koczywas M; Reckamp K; Salgia R
Lung Cancer; 2020 Aug; 146():174-181. PubMed ID: 32554069
[TBL] [Abstract][Full Text] [Related]
39. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
Wu Q; Liu J; Wu S; Xie X
Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
